Our cutting-edge solutions enhance the efficacy of cancer immunotherapies through advanced mRNA technology.
01
Metastatic cancers – Immune checkpoint Inhibitors
Our technology markedly enhances the therapeutic efficacy of immune checkpoint inhibitors (ICIs) across multiple preclinical models of metastatic cancers, including subtypes in which ICIs alone show no therapeutic activity (e.g., ER⁺ breast cancer).
02
Other immunotherapies
Our technology demonstrates strong synergistic efficacy not only with immune checkpoint inhibitors (ICIs) but also with other classes of immunotherapies, including adoptive cell transfer approaches such as CAR-T cell and tumor-infiltrating lymphocyte (TIL) therapies.
03
Microbial infections
Through enhancement of the global Antigen Presentation Machinery (APM), our technology extends its efficacy beyond oncology, showing strong potential against microbial infections, including emerging viral infections / Disease X.
04
Animal Health
Our technology also holds strong potential in the animal health market, with applications in both oncology and infectious disease, particularly in companion and sport animals such as dogs, cats, and horses.
Join Us to give hope to metastatic cancer patients
Join us in our mission to revolutionize cancer treatments and enhance patient outcomes.
